Biotinylated Human IgE Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00107P-100UG

Biotinylated Human IgE on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Biotinylated Human IgE Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00107P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Human IgE Protein is expressed from HEK293 with His and Avi tag at the C-Terminus.It contains Cys209-Lys428. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P01854 |
Target Symbol | IgE |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Cys209-Lys428 |
Mol. Weight | The protein has a predicted MW of 27.8 kDa. Due to glycosylation, the protein migrates to 32-38 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Biotinylated Human IgE, His Tag at 0.5ug/ml (100ul/well) on the streptavidin precoated plate (5ug/ml). Dose response curve for Anti-IgE Antibody, hFc Tag with the EC50 of 5.0ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Immunoglobulin E (IgE) is well known for its role in allergic disease, the manifestations of which are mediated through its two Fc receptors, FcεRI and CD23 (FcεRII). IgE and its interactions with these receptors are therefore potential targets for therapeutic intervention, and exciting progress has been made in this direction. Furthermore, recent structural studies of IgE-Fc, the two receptors, and of their complexes, have revealed a remarkable degree of plasticity at the IgE-CD23 interface and an even more remarkable degree of dynamic flexibility within the IgE molecule. |